Patent ID: 7662785

Claim:
A polydentate selective high affinity ligand (SHAL) that binds to a cancer cell bearing an HLA-DR10 surface antigen, said SHAL comprising: a first ligand that binds to an HLA-DR10 surface antigen linked to a second ligand that binds to an HLA DR10 surface antigen, where said first ligand is selected from the group consisting of 5(6) carboxytetramethylrhodamine-n-succinimidyl ester, Methidiumpropyl EDTA, Deoxycholic acid, FMOC-aspartic acid(O-benzyl)-OH, 4-dimethylaminoazobenzene-4′-sulfonyl-L-valine, 4-[[5-(trifluoromethyl)pyridin-2-yl]oxy]phenyl N-phenylcarbamate, N-alpha benzoyl-arginine-4-amino benzoic acid, 5-leu-enkephalin (YAGFM), N alpha N omega dicarbobenzoxyarginine, Angiotensin II (DRVY), Bis-BOC-L-arginine, 3,3′,5-Triiodo-dl-thyronine (Predicted Site 2) (TI), 2-(4-Chlorophenyl)-2-[6-[(4-chlorophenyl)suflfanyl]-3-pyridazinyl]acetamide (12F), 4-Amino-2-anilino-5-benzoyl-3-thiophenecarbonitrile (5K), 6-Chloro-n4-(4-phenoxyphenyl)-2,4-pyrimidinediamine (7L), N-(4-[[3-Chloro-5(trifluoromethyl)-2-pyridinyl]methyl]phenyl)-4-iodobenzenecarboxamide (6J), 5(6)-Carboxytetramethylrhodamine n-succinimidyl ester, N,N′-bis-(4-amino-2-chloro-phenyl)-terephthalamide4-[[5-(trifluoromethyl)pyridin-2-yl]oxy]phenyl N-phenylcarbamate, and Asp-Arg-Val-Tyr (SEQ ID NO:9), and said second ligand is independently selected from the ligands of Tables 2, 3, 4, or 5, and said first ligand and said second ligand are different ligands and bind to different sites on HLA-DR 10, and where said first ligand is linked to said second ligand by a linker comprising polyethylene glycol or a linker comprising lysine and polyethylene glycol.